Compare ORBS & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ORBS | IMRX |
|---|---|---|
| Founded | 1966 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 262.0M | 288.6M |
| IPO Year | 2022 | 2021 |
| Metric | ORBS | IMRX |
|---|---|---|
| Price | $0.73 | $5.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $17.20 |
| AVG Volume (30 Days) | ★ 11.9M | 748.7K |
| Earning Date | 04-14-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.75 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $31,820,779.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.57 | $3.25 |
| 52 Week High | $15.96 | $10.08 |
| Indicator | ORBS | IMRX |
|---|---|---|
| Relative Strength Index (RSI) | 55.04 | 63.56 |
| Support Level | $0.58 | $4.82 |
| Resistance Level | $0.96 | $5.27 |
| Average True Range (ATR) | 0.05 | 0.24 |
| MACD | 0.02 | 0.11 |
| Stochastic Oscillator | 80.21 | 88.21 |
Eightco Holdings Inc operates in Forever 8 Inventory Cash Flow Solution. The company is a dynamic technology-focused company committed to driving growth and innovation through strategic acquisitions and management. Forever 8 focuses on purchasing inventory for e-commerce retailers and is part of its Inventory Solution Business. Corrugated Packaging Business manufactured and sold custom packaging for a wide products and through packaging helps customers generate brand awareness and promote brand image. Generate the substantial majority of revenues from inventory financing and inventory management services.
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.